215 related articles for article (PubMed ID: 28783399)
1. Outcome measures of disease activity in inflammatory arthritis.
Brown GA; Cotton A; Guinto J; Sharma A; Ciurtin C
Br J Hosp Med (Lond); 2017 Aug; 78(8):432-437. PubMed ID: 28783399
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of Quality Measures for Inflammatory Arthritis.
Cooper M; Rouhi A; Barber CEH
J Rheumatol; 2018 Feb; 45(2):274-283. PubMed ID: 29142026
[TBL] [Abstract][Full Text] [Related]
3. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future.
Schett G; Coates LC; Ash ZR; Finzel S; Conaghan PG
Arthritis Res Ther; 2011 May; 13 Suppl 1(Suppl 1):S4. PubMed ID: 21624183
[TBL] [Abstract][Full Text] [Related]
4. Outcome measures in psoriatic arthritis clinical trials.
Reddy SM; Bingham III CO
Curr Rheumatol Rep; 2005 Aug; 7(4):299-305. PubMed ID: 16045833
[TBL] [Abstract][Full Text] [Related]
5. The definition and measurement of disease modification in inflammatory rheumatic diseases.
Aletaha D; Smolen JS
Rheum Dis Clin North Am; 2006 Feb; 32(1):9-44, vii. PubMed ID: 16504819
[TBL] [Abstract][Full Text] [Related]
6. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Kvamme MK; Kristiansen IS; Lie E; Kvien TK
J Rheumatol; 2010 Jan; 37(1):26-31. PubMed ID: 19955045
[TBL] [Abstract][Full Text] [Related]
7. Measures of outcome in ankylosing spondylitis and other spondyloarthritides.
van der Heijde DM; van der Linden S
Baillieres Clin Rheumatol; 1998 Nov; 12(4):683-93. PubMed ID: 9928502
[TBL] [Abstract][Full Text] [Related]
8. Nonpharmacologic Pain Management in Inflammatory Arthritis.
Martin A; Chopra R; Nicassio PM
Rheum Dis Clin North Am; 2021 May; 47(2):277-295. PubMed ID: 33781495
[TBL] [Abstract][Full Text] [Related]
9. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.
Huscher D; Merkesdal S; Thiele K; Zeidler H; Schneider M; Zink A;
Ann Rheum Dis; 2006 Sep; 65(9):1175-83. PubMed ID: 16540552
[TBL] [Abstract][Full Text] [Related]
10. [Adherence to biological therapies in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. (Study ADhER-1)].
Núñez-Rodríguez J; González-Pérez Y; Nebot-Villacampa MJ; Zafra-Morales R; Obaldia-Alaña MC; Caso-González A
Semergen; 2021 Mar; 47(2):81-90. PubMed ID: 32778364
[TBL] [Abstract][Full Text] [Related]
11. Anti cytokine therapy in chronic inflammatory arthritis.
Thompson C; Davies R; Choy E
Cytokine; 2016 Oct; 86():92-99. PubMed ID: 27497159
[TBL] [Abstract][Full Text] [Related]
12. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Voulgari PV
Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
[TBL] [Abstract][Full Text] [Related]
13. [RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA].
Anić B; Babić-Naglić Ð; Grazio S; Kehler T; Kaliterna DM; Radoncić KM; Morović-Vergles J; Novak S; Prus V; Vlak T; Baresić M
Reumatizam; 2015; 62(1):12-9. PubMed ID: 27024887
[TBL] [Abstract][Full Text] [Related]
14. Extra-articular manifestations.
Mielants H; Van den Bosch F
Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S56-61. PubMed ID: 19822047
[TBL] [Abstract][Full Text] [Related]
15. Comment on 'Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry'.
Feldtkeller E; Rudwaleit M
Ann Rheum Dis; 2014 Dec; 73(12):e77. PubMed ID: 25252720
[No Abstract] [Full Text] [Related]
16. Summary of Sensitivity and Specificity for Psoriatic Arthritis in a South African Cohort according to Classification Criteria.
Maharaj AB; Govender J; Maharaj K; Rajkaran M; Tak PP
J Rheumatol; 2015 Jun; 42(6):960-2. PubMed ID: 25877500
[TBL] [Abstract][Full Text] [Related]
17. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Campas-Moya C
Drugs Today (Barc); 2010 Jan; 46(1):13-22. PubMed ID: 20200692
[TBL] [Abstract][Full Text] [Related]
18. Therapies for psoriatic enthesopathy. A systematic review.
Ritchlin CT
J Rheumatol; 2006 Jul; 33(7):1435-8. PubMed ID: 16724370
[TBL] [Abstract][Full Text] [Related]
19. Therapies for axial disease in psoriatic arthritis. A systematic review.
Nash P
J Rheumatol; 2006 Jul; 33(7):1431-4. PubMed ID: 16724371
[TBL] [Abstract][Full Text] [Related]
20. Spondyloarthropathies.
Kataria RK; Brent LH
Am Fam Physician; 2004 Jun; 69(12):2853-60. PubMed ID: 15222650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
